Do Regulatory Bioequivalence Requirements Adequately Reflect the Therapeutic Equivalence of Modified-Release Drug Products?
Purpose. To demonstrate that current regulatory requirements for bioequivalence (BE) do not always reflect therapeutic equivalence. To investigate the potential usefulness of an additional metric, the partial AUC. Methods. Pharmacokinetic information was reviewed and evaluated on the pharmacokinetic...
Saved in:
Main Authors: | Laszlo Endrenyi (Author), Laszlo Tothfalusi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2010-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden
by: Laszlo Endrenyi, et al.
Published: (2013) -
Regulatory and Study Conditions for the Determination of Bioequivalence of Highly Variable Drugs
by: Laszlo Endrenyi, et al.
Published: (2009) -
Sample Sizes for Designing Bioequivalence Studies for Highly Variable Drugs
by: Laszlo Endrenyi, et al.
Published: (2011) -
Rethinking bioequivalence and equivalence requirements of orally inhaled drug products
by: Dina Al-Numani, et al.
Published: (2015) -
Assessing Bioequivalence of Antiepileptic Drugs: Are the Current Requirements too Permissive?
by: Camila F Rediguieri, et al.
Published: (2014)